No Data
No Data
Express News | Guggenheim Reiterates Buy on Dyne Therapeuticsto Buy
Express News | Dyne Therapeutics Inc : JP Morgan Cuts Target Price to $18 From $34
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $60
Dyne Gets FDA Fast-Track Status for Neuromuscular Product Candidate
Express News | Dyne Therapeutics Inc - to Submit for U.S. Accelerated Approval in H1 2026